Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update

Journal of the American College of Cardiology

Volumn 43, Issue 5, 2004, Pages 717-724

  Gotto Jr , Antonio M ^a   Brinton, Eliot A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

ABC A1; Adenosine triphosphate binding cassette A1; Apo; Apolipoprotein; CETP; CHD; Cholesteryl ester transfer protein; Coronary heart disease; FCR; Fractional catabolic rate; HDL C; Hepatic lipase; High density lipoprotein cholesterol; HL; LCAT

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOLIPOPROTEIN A1; ATENOLOL; ATORVASTATIN; BIOCHEMICAL MARKER; CHLORTALIDONE; DOXAZOSIN; ESTROGEN; ETC 216; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VACCINE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EXPERIMENT; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEMOCONCENTRATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PHYSICAL ACTIVITY; PLASMA FACTOR; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STIMULATION; SUSTAINED RELEASE PREPARATION; TRANSPORT KINETICS;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 1542361567     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.08.061     Document Type: Review

References (81)

1. Tailleux A., Duriez P., Fruchart J.-C., Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 164:2002;1-13.
2. Brinton E.A., Eisenberg S., Breslow J.L. Elevated high-density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 84:1989;262-269.
3. Brinton E.A., Eisenberg S., Breslow J.L. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein- cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 87:1991;536-544.
4. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arterioscler Thromb. 14:1994;707-720.
5. Gylling H., Miettinen T.A. Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes. J Lipid Res. 33:1992;1361-1371.
6. De Oliveira e Silva E., Foster D., Harper M.M., et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation. 102:2000;2347-2352.
7. Brinton E.A., Eisenberg S., Breslow J.L. A low-fat diet decreases high-density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest. 85:1990;144-151.
8. Rader D.J., Ikewaki K. Unraveling high density lipoprotein- apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol. 7:1996;117-123.
9. Hayden M.R., Blee S.M., Brooks-Wilson A., et al. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol. 11:2000;117-122.
10. Oram J.F., Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 37:1996;2473-2491.
11. Brousseau M.E., Eberhart G.P., Dupuis J., et al. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res. 41:2000;1125-1135.
12. Mott S., Yu L., Marcil M., et al. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia Role of the abca1 gene mutations. Atherosclerosis. 152:2000;457-468.
13. Nanjee M.N., Brinton E.A. Very small apolipoprotein A-I-containing particles from human plasma Isolation and quantification by high-performance size-exclusion chromatography. Clin Chem. 46:2000;207-223.
14. Hayek T., Azrolan N., Verdery R.B., et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J Clin Invest. 92:1993;1143-1152.
15. Jin F.-Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Arterioscler Thromb Vasc Biol. 17:1997;2020-2028.
16. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;1088-2093.
17. Schaefer J.R., Schweer H., Ikewaki K., et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis. 144:1999;177-184.
18. Brinton E.A. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol. 16:1996;431-440.
19. Zhang Y., Repa J.J., Gauthier K., Mangelsdorf D.J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ J Biol Chem. 276:2001;43018-43024.
20. Barter P.J., Rye K.A. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol. 7:1996;82-87.
21. Krause B.R., Auerbach B.J. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Investig Drugs. 2:2001;375-381.
22. Quintão E.C.R. Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Atherosclerosis. 116:1995;1-14.
23. Kozyraki R. Cubilin, a multifunctional epithelial receptor An overview. J Mol Med. 79:2001;161-167.
24. Joyce C.W., Amar M.J., Lambert G., et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE knockout mice. Proc Natl Acad Sci USA. 99:2002;407-412.
25. Cavelier L.B., Qiu Y., Bielicki J.K., et al. Regulation and activity of the human ABCAA1 gene in transgenic mice. J Biol Chem. 276:2001;18046-18051.
26. Schmitz G., Langmann T., Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 42:2001;1513-1520.
27. Ito T, Sabol SL, Amar M, et al. Adenovirus-mediated expression establishes an in vivo role for human ABCG1 (ABC8) in lipoprotein metabolism. Scientific Sessions 2000 of the American Heart Association; New Orleans, Louisiana, November 12-15, 2000 (abstr). Circulation 2000;102:311.
28. Varban M.L., Rinninger F., Wang N., et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci USA. 95:1998;4619-4624.
29. Yamakawa-Kobayashi K., Yanagi H., Fukayama H., et al. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population A population-based survey. Hum Mol Genet. 8:1999;331-336.
30. Sorci-Thomas M.G., Thomas M.J. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med. 12:2002;121-128.
31. Zambon A., Deeb S.S., Brown B.G., et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 103:2001;792-798.
32. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 338:1998;86-93.
33. Shah P.K. Plaque disruption and coronary thrombosis New insight into pathogenesis and prevention. Clin Cardiol. 20:(Suppl II):1997;II38-II44.
34. Artl A., Marsche G., Lestavel S., et al. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 20:2000;763-772.
35. Volpato S., Palmieri E., Fellin R., et al. Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalized elderly patients. Gerontology. 46:2000;22-27.
36. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes proinflammatory during the acute-phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 96:1995;2758-2767.
37. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol. 88:(Suppl):2001;9N-13N.
38. Glueck C.J., Fallat R.W., Millett F., et al. Familial hyper-alpha-lipoproteinemia Studies in eighteen kindreds. Metabolism. 24:1975;1243.
39. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. An idea whose time for testing is coming, part I. Circulation. 104:2001;2376-2383.
40. Duverger N., Kruth H., Emmanuel F., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation. 94:1996;713-717.
41. Franceschini G., Calabresi L., Chiesa G., et al. Increased cholesterol efflux potential of sera from ApoA-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 19:1999;1257-1262.
42. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA. 290:2003;2292-2300.
43. (-/-) mice. Arterioscler Thromb Vasc Biol. 21:2001;1790-1795.
44. Neve B., Fruchart J.C., Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol. 60:2000;1245-1250.
45. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs) Nuclear receptors with functions in the vascular wall. Z Kardiol. 90:(Suppl 3):2001;125-132.
46. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation, and atherosclerosis. Curr Opin Lipidol. 10:1999;245-257.
47. Berger J., Leibowitz M.D., Doebber T.W., et al. Novel peroxisome proliferator-activated receptor (PPAR)-γ and PPAR-δ ligands produce distinct biological effects. J Biol Chem. 274:1999;6718-6725.
48. Chinetti G., Lestabel S., Bocher V., et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 7:2001;53-58.
49. Martin G., Duez H., Blanquart C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest. 107:2001;1423-1432.
50. Spiegelman B.M. PPAR-γ Adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
51. Kozarsky K.F., Donahee M.H., Glick J.M., et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 20:2000;721-727.
52. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
53. Rittershaus C.W., Miller D.P., Thomas L.J., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;2106-2112.
54. Inazu A., Koizumi J., Mabuchi H. Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol. 11:2000;389-396.
55. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
56. Lyon C.J., Law R.E., Hsueh W.A. Mini-review Adiposity, inflammation, and atherogenesis. Endocrinology. 144:2003;2195-2200.
57. Carmena R., Ascaso J.F., Real J.T. Impact of obesity in primary hyperlipidemias. Nutr Metab Cardiovasc Dis. 11:2001;354-359.
58. Vajo Z., Terry J.G., Brinton E.A. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis. 160:2002;495-501.
59. Scott C.L. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol. 92:(Suppl):2003;35-42i.
60. Miyazaki Y., Mahankali A., Matsuda M., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 24:2001;710-719.
61. Rader D.J. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. Am J Cardiol. 91:(Suppl):2003;18E-23E.
62. Nofer J.R., Kehrel B., Fobker M., et al. HDL and arteriosclerosis Beyond reverse cholesterol transport. Atherosclerosis. 161:2002;1-16.
63. Tangirala R.K., Pratico D., FitzGerald G.A., et al. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem. 276:2001;261-266.
64. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 14:1996;55-61.
65. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
66. Sakai T., Kamanna V.S., Kashyap M. Niacin, but not gemfibrozil, selectively increases Lp-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 21:2001;1783-1789.
67. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients Long-term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255.
68. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
69. Brown B.G., Zhao X.-Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
70. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels Results of afcaps/texcaps. JAMA. 279:1998;1615-1622.
71. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
72. Herd J.A., Ballantyne C.M., Farmer J.A. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study. [LCAS]) Am J Cardiol. 80:1997;278-286.
73. Davidson M., Ma P., Stein E.A., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 89:2002;268-275.
74. Hunninghake D.B., McGovern M.E., Koren M., et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. 26:2003;112-118.
75. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
76. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events Va-hit: a randomized controlled trial. JAMA. 285:2001;1585-1591.
77. Andersen P., Seljeflot I., Herzog A., et al. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men. J Cardiovasc Pharmacol. 31:1998;677-683.
78. Glanz M., Garber A.J., Mancia G., et al. Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes. Int J Clin Pract. 55:2001;694-701.
79. Yildiz A., Hursit M., Celik A.V., et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure A prospective, randomized controlled study. Clin Nephrol. 58:2002;405-410.
80. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75.
81. Miller M. Raising an isolated low HDL-C level Why, how, and when? Cleve Clinic J Med. 70:2003;553-560.